TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression

Hepatocellular carcinoma (HCC) is associated with high mortality and the current therapy for advanced HCC, Sorafenib, offers limited survival benefits. Here we assessed whether combining the TLR3 agonist: lysine-stabilized polyinosinic-polycytidylic-acid (poly-ICLC) with Sorafenib could enhance tumo...

Descripción completa

Detalles Bibliográficos
Autores principales: Ho, Victor, Lim, Tong Seng, Lee, Justin, Steinberg, Jeffrey, Szmyd, Radoslaw, Tham, Muly, Yaligar, Jadegoud, Kaldis, Philipp, Abastado, Jean-Pierre, Chew, Valerie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694987/
https://www.ncbi.nlm.nih.gov/pubmed/26287667

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694987/
https://www.ncbi.nlm.nih.gov/pubmed/26287667

Ejemplares similares